WEBINAR | Avidity Biosciences Announces Positive Data
August 16 @ 9:00 am - 10:00 am
Description: EXPLORE44 is a Phase 1/2 clinical trial evaluating Del-zota (AOC1044) for the treatment of individuals with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44)
Learn more here
We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you are agreeing to accept our use of cookies. For more information about cookies please visit our Privacy Policy page.I Agree